4D Molecular Therapeutics (FDMT) Institutional Ownership

During the previous two years, 139 institutional investors and hedge funds held shares of 4D Molecular Therapeutics. The most heavily invested institutionals were RA Capital Management L.P. ($25.42M), State Street Corp ($22.88M), VR Adviser LLC ($16.45M), Novo Holdings A S ($16.22M), Vanguard Group Inc. ($15.93M), BVF Inc. IL ($14.73M), and Goldman Sachs Group Inc. ($13.46M).Learn more on FDMT's institutional investors.

99.27% of 4D Molecular Therapeutics stock is owned by institutional investors. Learn more on FDMT's institutional investor holdings.

Of the 118 institutional investors that purchased 4D Molecular Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: RA Capital Management L.P. ($5.05M), VR Adviser LLC ($3M), BVF Inc. IL ($1.89M), Millennium Management LLC ($1.55M), Assenagon Asset Management S.A. ($1.54M), Redmile Group LLC ($1.45M), and Federated Hermes Inc. ($1.25M).

Institutional investors have bought a total of 26,696,964 shares in the last 24 months. This purchase volume represents approximately $404.54M in transactions.

Of the 54 institutional investors that sold 4D Molecular Therapeutics stock in the last 24 months, the following investors and hedge funds have sold the highest volume of shares: BVF Inc. IL ($4.80M), Deep Track Capital LP ($3.49M), VR Adviser LLC ($1.45M), FMR LLC ($1.01M), Janus Henderson Group PLC ($944.52K), Assenagon Asset Management S.A. ($889.88K), and Deutsche Bank AG ($566.48K).

Institutional investors have sold a total of 16,940,875 shares in the last 24 months. This volume of shares sold represents approximately $117.65M in transactions.